Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Genitourinary 2Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Acetaminophen × Genitourinary × Clear all
NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
59 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

NCT02933255 2024-05-31

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
24 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡